Evidence for L‐dopa incorporation into cell proteins in patients treated with levodopa

Kenneth Rodgers, Peter Hume, John Morris, Roger Dean

    Research output: Contribution to journalArticle

    24 Citations (Scopus)

    Abstract

    Levodopa (L-dopa) is the most widely used agent for the symptomatic relief of Parkinson's disease. There is concern that chronic L-dopa treatment may be detrimental, with some studies suggesting that L-dopa may be neurotoxic. A potentially important mechanism whereby L-dopa may exert neurotoxic effects has been overlooked: that of the incorporation of L-dopa into proteins by protein synthesis. L-Dopa competes with tyrosine as a substrate in protein synthesis in vitro. We provide evidence that L-dopa can also be incorporated into proteins in vivo. Blood from L-dopa-treated and -non-treated patients was separated into protein, erythrocyte and lymphocyte fractions and levels of protein-incorporated dopa quantified by HPLC. Levels of protein-incorporated dopa were significantly increased in lymphocyte cell proteins from L-dopa-treated patients. This has not arisen from oxidative pathways as there was no evidence of oxidative damage to proteins. In addition, there was no increase in protein-incorporated dopa in erythrocytes, which are not actively synthesizing proteins. We suggest that protein-incorporated dopa could also be generated in the CNS. The accumulation of protein-incorporated dopa in cells is associated with oxidative stress and impaired function and could contribute to some of the problems associated with long-term L-dopa treatment.
    Original languageEnglish
    Pages (from-to)1061-1067
    Number of pages7
    JournalJournal of Neurochemistry
    Volume98
    Issue number4
    DOIs
    Publication statusPublished - 2006

    Fingerprint

    Levodopa
    Dihydroxyphenylalanine
    Proteins
    Lymphocytes
    Secondary Parkinson Disease
    Erythrocytes
    Oxidative stress
    Tyrosine
    Oxidative Stress
    Blood
    High Pressure Liquid Chromatography

    Cite this

    Rodgers, Kenneth ; Hume, Peter ; Morris, John ; Dean, Roger. / Evidence for L‐dopa incorporation into cell proteins in patients treated with levodopa. In: Journal of Neurochemistry. 2006 ; Vol. 98, No. 4. pp. 1061-1067.
    @article{de5432270b4d4a388a20911095a1c533,
    title = "Evidence for L‐dopa incorporation into cell proteins in patients treated with levodopa",
    abstract = "Levodopa (L-dopa) is the most widely used agent for the symptomatic relief of Parkinson's disease. There is concern that chronic L-dopa treatment may be detrimental, with some studies suggesting that L-dopa may be neurotoxic. A potentially important mechanism whereby L-dopa may exert neurotoxic effects has been overlooked: that of the incorporation of L-dopa into proteins by protein synthesis. L-Dopa competes with tyrosine as a substrate in protein synthesis in vitro. We provide evidence that L-dopa can also be incorporated into proteins in vivo. Blood from L-dopa-treated and -non-treated patients was separated into protein, erythrocyte and lymphocyte fractions and levels of protein-incorporated dopa quantified by HPLC. Levels of protein-incorporated dopa were significantly increased in lymphocyte cell proteins from L-dopa-treated patients. This has not arisen from oxidative pathways as there was no evidence of oxidative damage to proteins. In addition, there was no increase in protein-incorporated dopa in erythrocytes, which are not actively synthesizing proteins. We suggest that protein-incorporated dopa could also be generated in the CNS. The accumulation of protein-incorporated dopa in cells is associated with oxidative stress and impaired function and could contribute to some of the problems associated with long-term L-dopa treatment.",
    author = "Kenneth Rodgers and Peter Hume and John Morris and Roger Dean",
    year = "2006",
    doi = "10.1111/j.1471-4159.2006.03941.x",
    language = "English",
    volume = "98",
    pages = "1061--1067",
    journal = "Journal of Neurochemistry",
    issn = "0022-3042",
    publisher = "Wiley-Blackwell",
    number = "4",

    }

    Evidence for L‐dopa incorporation into cell proteins in patients treated with levodopa. / Rodgers, Kenneth; Hume, Peter; Morris, John; Dean, Roger.

    In: Journal of Neurochemistry, Vol. 98, No. 4, 2006, p. 1061-1067.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Evidence for L‐dopa incorporation into cell proteins in patients treated with levodopa

    AU - Rodgers, Kenneth

    AU - Hume, Peter

    AU - Morris, John

    AU - Dean, Roger

    PY - 2006

    Y1 - 2006

    N2 - Levodopa (L-dopa) is the most widely used agent for the symptomatic relief of Parkinson's disease. There is concern that chronic L-dopa treatment may be detrimental, with some studies suggesting that L-dopa may be neurotoxic. A potentially important mechanism whereby L-dopa may exert neurotoxic effects has been overlooked: that of the incorporation of L-dopa into proteins by protein synthesis. L-Dopa competes with tyrosine as a substrate in protein synthesis in vitro. We provide evidence that L-dopa can also be incorporated into proteins in vivo. Blood from L-dopa-treated and -non-treated patients was separated into protein, erythrocyte and lymphocyte fractions and levels of protein-incorporated dopa quantified by HPLC. Levels of protein-incorporated dopa were significantly increased in lymphocyte cell proteins from L-dopa-treated patients. This has not arisen from oxidative pathways as there was no evidence of oxidative damage to proteins. In addition, there was no increase in protein-incorporated dopa in erythrocytes, which are not actively synthesizing proteins. We suggest that protein-incorporated dopa could also be generated in the CNS. The accumulation of protein-incorporated dopa in cells is associated with oxidative stress and impaired function and could contribute to some of the problems associated with long-term L-dopa treatment.

    AB - Levodopa (L-dopa) is the most widely used agent for the symptomatic relief of Parkinson's disease. There is concern that chronic L-dopa treatment may be detrimental, with some studies suggesting that L-dopa may be neurotoxic. A potentially important mechanism whereby L-dopa may exert neurotoxic effects has been overlooked: that of the incorporation of L-dopa into proteins by protein synthesis. L-Dopa competes with tyrosine as a substrate in protein synthesis in vitro. We provide evidence that L-dopa can also be incorporated into proteins in vivo. Blood from L-dopa-treated and -non-treated patients was separated into protein, erythrocyte and lymphocyte fractions and levels of protein-incorporated dopa quantified by HPLC. Levels of protein-incorporated dopa were significantly increased in lymphocyte cell proteins from L-dopa-treated patients. This has not arisen from oxidative pathways as there was no evidence of oxidative damage to proteins. In addition, there was no increase in protein-incorporated dopa in erythrocytes, which are not actively synthesizing proteins. We suggest that protein-incorporated dopa could also be generated in the CNS. The accumulation of protein-incorporated dopa in cells is associated with oxidative stress and impaired function and could contribute to some of the problems associated with long-term L-dopa treatment.

    U2 - 10.1111/j.1471-4159.2006.03941.x

    DO - 10.1111/j.1471-4159.2006.03941.x

    M3 - Article

    VL - 98

    SP - 1061

    EP - 1067

    JO - Journal of Neurochemistry

    JF - Journal of Neurochemistry

    SN - 0022-3042

    IS - 4

    ER -